Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOST | Q9BQB4 | 1/20 | 0.77 |
| ▸ | FPGS | Q05932 | 2/20 | 0.76 |
| ▸ | GART | P22102 | 5/20 | 0.57 |
| ▸ | DHFR | P00374 | 1/20 | 0.52 |
| ▸ | ATIC | P31939 | 2/20 | 0.50 |
| ▸ | MTHFD1 | P11586 | 2/20 | 0.48 |
| ▸ | NOS1 | P29475 | 2/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MTHFD2 | P13995 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4334665 | 0.93 | SOST (0.76) | SOSTFPGSGARTDHFRATIC | |
| SCHEMBL28206357 | 0.90 | SOST (0.79) | SOSTFPGSGARTDHFRATIC | |
| SCHEMBL50298 | 0.90 | SOST (0.78) | SOSTFPGSGARTDHFRATIC | |
| SCHEMBL15121249 | 0.90 | SOST (0.78) | SOSTFPGSGARTDHFRATIC | |
| SCHEMBL716106 | 0.90 | SOST (0.78) | SOSTFPGSGARTDHFRATIC | |
| SCHEMBL3953439 | 0.90 | SOST (0.78) | SOSTFPGSGARTDHFRATIC | |
| SCHEMBL27363888 | 0.90 | FPGS (0.75) | SOSTFPGSGARTDHFRATIC | |
| SCHEMBL27708884 | 0.89 | SOST (0.77) | SOSTFPGSGARTDHFRATIC | |
| SCHEMBL28469783 | 0.89 | SOST (0.77) | SOSTFPGSGARTDHFRATIC | |
| SCHEMBL717287 | 0.88 | SOST (0.76) | SOSTFPGSGARTDHFRATIC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001030352-A1 | HIGH DOSE FOLIC ACID FOR THE TREATMENT OF HYPERHOMOCYSTEINEMIA | CARY PHARMACEUTICALS INC. (US) | 2001-05-03 | — | — | WO | claimed |
| US-20170258861-A1 | Treatment of Herpes, Pseudomonas, Staph, and Hepatitis | SQUIRES MERYL J (US) | 2017-09-14 | — | — | US | disclosed |
| US-9662360-B2 | Treatment of herpes, pseudomonas, staph, and hepatitis | MERITUS CORPORATION (DM) | 2017-05-30 | — | — | US | disclosed |
| US-20160151436-A1 | Treatment of Herpes, Pseudomonas, Staph, and Hepatitis | MERITUS CORPORATION (DM) | 2016-06-02 | — | — | US | disclosed |
| US-20090191288-A1 | Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases | SQUIRES MERYL J | 2009-07-30 | — | — | US | disclosed |
| US-7071233-B2 | Antimicrobial prevention and treatment of human immunedeficience virus and other infectious diseases | Squires, Meryl J. (US) | 2006-07-04 | — | — | US | disclosed |
| US-6646013-B1 | Synergystic mixtures of salicin, curcumin, calcium, folic acid, vitamins D, B6 and B12, used to prevent colon and rectal cancer in humans | NUTRI-LOGICS | 2003-11-11 | — | — | US | disclosed |
| EP-1200075-A4 | NUTRIENT FORMULATIONS FOR DISEASE REDUCTION, AND RELATED TREATMENT AND COMPONENT SCREENING METHODS | NUTRI LOGICS INC (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-1200075-A1 | NUTRIENT FORMULATIONS FOR DISEASE REDUCTION, AND RELATED TREATMENT AND COMPONENT SCREENING METHODS | Nutri-Logics, Inc. (US) | 2002-05-02 | — | — | EP | disclosed |
| US-6350784-B1 | PHYTOCHEMICALS, SURFACTANT, FOLIC ACID, | Squires, Meryl J. | 2002-02-26 | — | — | US | disclosed |
| WO-2001030352-A1 | HIGH DOSE FOLIC ACID FOR THE TREATMENT OF HYPERHOMOCYSTEINEMIA | CARY PHARMACEUTICALS INC. (US) | 2001-05-03 | — | — | WO | disclosed |
| WO-2000076492-A1 | NUTRIENT FORMULATIONS FOR DISEASE REDUCTION, AND RELATED TREATMENT AND COMPONENT SCREENING METHODS | NUTRI-LOGICS, INC. (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160151436-A1 | Treatment of Herpes, Pseudomonas, Staph, and Hepatitis | NISCH, CUTA, HRH1 | SOST 3298/4885FPGS 4528/4885GART 606/4885 |
| US-20170258861-A1 | Treatment of Herpes, Pseudomonas, Staph, and Hepatitis | NISCH, CUTA, HRH1 | SOST 3298/4885FPGS 4528/4885GART 606/4885 |
| US-20090191288-A1 | Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases | ASPH, KCNH3, PRPH | SOST 3260/4885FPGS 4697/4885GART 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.